AAV vector production workflow

How to overcome AAV manufacturing challenges

Adeno-associated virus (AAV) vectors have emerged as a promising tool for gene therapy, holding tremendous potential to treat a wide array of genetic disorders. However, the journey from lab to commercial production has not been without obstacles. In this video, we'll explore valuable insights into challenges and triumphs of AAV manufacturing.

ELEVECTA™ producer cell line webpage card image 265 x 265

Robust and scalable AAV production

Read about the upstream process development and optimization of AAV production in batch and perfusion modes.

Adherent cell process

Read about the scalable upstream process we developed for rAAV8 in HEK293 cells.

Suspension cell process

Learn how we developed a scalable, cGMP compatible process in a stirred-tank, single-use bioreactor.

Effective separation of full and empty adeno associated virus capsids by anion exchange

Effective AAV polishing

See how we achieved baseline separation of full and empty capsids with ~ 80% VG recovery and purity.

Gene therapy AAV vectors

Adeno-associated viral (AAV) vectors are a common delivery system for gene therapies with advantages including enhanced safety compared to other vectors. A variety of AAV serotypes target different tissues to support a variety of therapeutic applications, but they all share common manufacturing challenges and solutions.

Why AAV?

AAV workflow webpage content block image 520 x 300

Process development services

Use our know-how to simplify and accelerate your development and meet your process milestones.

Learn more

Pioneer the new era with the right cell line

Prevalent indications are the next frontier for adeno-associated virus (AAV)-based gene therapy. Transient transfection is simple but not efficient or scalable enough. An ELEVECTA™ producer cell line contains all genes to produce rAAV; simply induce. The result is a simplified and robust upstream process that easily scales to treat hundreds of thousands.

Start now